a b s t r a c t Data presented in this Data in Brief article correspond to the article "in vivo" silencing of CD40 reduces progression of experimental atherogenesis through a NFκB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis" (M. Hueso, L. De Ramon, E. Navarro, E. Ripoll, J.M. Cruzado, J.M. Grinyo, J. Torras, 2016) [1]
ApoE À / À intraperitoneally-treated with an anti-CD40 specific siRNA
Experimental features
Expression of mRNAs/miRNAs in the ascending aorta of ApoE À / À was compared with that of mice treated with a scrambled siRNA as control Data source location n.a
Data accessibility Data are available with this article
Value of the Data 1. CD40 was silenced "in vivo" with a specific siRNA in ApoE À / À mice. Silencing was confirmed by measuring CD40 expression by qPCR, IHC and flow-cytometry. 2. Infiltrating macrophages were detected in atherosclerotic aortas of ApoE À / À mice and its number decreased upon CD40 silencing. 3. Gene Ontology (GO) analysis targeted a number of components of the NF-kB pathway, as well as members of the Clec/Klr gene families as potentially involved in disease progression. Furthermore, TLDA profiling detected a number of murine miRNAs also potentially involved in disease progression. 4. This data provide evidences of the potency of the specific siRNA used.
Data
The dataset of this article provides information on the validation of the silencing of the CD40 gene in the aorta from ApoE-deficient mice upon treatment with a specific siCD40 [ Fig. 1 ], the description of their systemic effects in spleen cell subpopulations [ Table 1 ], and the quantification of the infiltration of macrophages and of NF-κB þ cells in their aortic plaques [ Fig. 2 ]. We also present a Gene Ontology (GO) analysis [ Fig. 3 ], centered in components of the NF-κB pathway [ Table 2 ], or in the Clec and Klr families [ Table 3 ], as well as a miRNA gene expression data analysis [ Table 4 ] during disease progression and upon siCD40 treatment. Finally we present the demographic data for the patients included in the accompanying study [ Table 5 ].
Experimental design, materials and methods

Study design
CD40 was silenced with a specific siRNA (siCD40) in ApoE À / À mice. Global patterns of expression of mRNAs/miRNAs in the ascending aorta were compared among siCD40 and SC-control treated mice. Table 1 Immunophenotype data analysis of spleen cell sub-populations from CD40-silenced in ApoE-deficient mice. 
Validation of CD40 silencing efficiency
CD40-silencing was validated by qPCR and IHC ( Fig. 1 ). Sections were evaluated by hematoxylin/ eosin staining and antigen-specific IHC using standard procedures.
Analysis of macrophage cell infiltration in plaques of ApoE-deficient mice treated with siCD40
F4/80 þ , galectin-3 þ , and NF-kB þ cells were detected and quantified by antigen-specific IHC using standard procedures (Fig. 2) . 
Evaluation of the systemic effect of CD40 silencing
Changes in splenic lymphoid cell subsets were characterizaed by using a BD FACS Canto II Cytometer after double or triple staining with monoclonal antibodies (Table 1 ). Splenocytes were isolated as previously described [2] and incubated with anti-CD19 APC (clone 1D3), anti-CD3 APC (clone 145-2C11), anti-CD4 PECY7 (clone RM4-5), anti-CD8 PERCP-CY5.5 (clone 53-6.7), anti-CD11c PE (clone HL3), anti-CD11b APC-CY7 Fig. 3 . GO charts for genes down-regulated in the stated experiments. Every pie portion stands for a functional group of genes and its size is proportional to the number of genes that belong to that group.
(cloneM1/70), anti-F4/80 PE (clone BM8), antiCD40 FITC (clone HM40-3), anti-CD86 FITC (Clone GL1), and anti-CD206 FITC (clone C068C2), all from BD Biosciences (BD Biosciences, San Jose, CA, USA). For each marker, results are expressed as percentage of the total number of cells acquired. Kruskal-Wallis test. *po0.05 by Bonferroni test to compare SC/24w vs siCD40/24w.
Gene Ontology (GO) analysis
RNA extraction, microarray hybridization and analysis were performed on a commercial basis at Arraystar Inc. (Rockville, MD, USA). Differentially expressed mRNAs were identified in Volcano plots by using the standard thresholds of log 2 (Fold Change)41 and À log 10 (P-Value) 41.30 [1] . The Gene Table 2 Gene Ontology data analysis (GO ¼Biological process/Immune system process/Immune response) centered on the genes encoding components of the NF-κB pathway. Ontology (GO) analysis (www.pantherdb.org) [3] [4] [5] was used to classify differentially expressed mRNAs by their functional roles. Genes which passed the volcano plot thresholds were arranged in pie charts ( Fig. 3 ) and then classified in "GO Biological process" categories. Transcripts belonging to the "Immune System Process" category (level 1, GO:0002376) were subsequently studied (Level 0 ¼Biological process, Level 1 ¼ Immune system process, (GO:0002376), and Level 2 ¼Immune Response (GO:0006955) [6] . Every pie portion stands for a functional group of genes and its size is proportional to the number of genes that belong to that group. Shown are genes of the NF-kB pathway ( Table 2) , and of the Clec/Klr family (Table 3 ).
Gene expression miRNA profiling of mouse aortas using TLDA cards
Total RNA from frozen aortic samples was studied by TLDA cards. MiRNA expression data from the TLDAs were analyzed with the ExpressionSuite Software v1.0.3 (Life Technologies) by using the ΔΔCt method after global normalization [7] . Differentially expressed miRNAs were identified in "Volcano plots. Expression changes are shown as log 2 Fold Change (log 2 FC) after comparing normalized expression for each experiment. Gene name (Gene), changes in expression (log 2 FC), and the statistical significance of the replicates ( À log 10 (PVal) are shown. In all cases the thresholds used were: log 2 FC 41 and À log 10 (PVal) 4 1.30. n.s.¼ either log 2 FC or À log 10 (PVal) were below the thresholds. Table 4 shows the most significant hits found. 
Demographics of human samples
Abdominal human aortas were collected from autopsy material from patients deceased in the HUB from November/2009-February/2010. Confidentiality was protected following national guidelines. The study was performed conform the declaration of Helsinki and approved by the Clinical Research Ethics Committee of HUB (PR163/13). Demographics of the patients involved in the study are shown in Table 5 .
